Takeda Reports FY2025 Net Loss, Forecasts FY2026 Revenue & Profit Decline Amid Investments
TAK sits 22% above its 52-week low of $12.99.
Summary
Takeda's Annual Integrated Report details a FY2025 net loss due to litigation and projects a FY2026 core revenue and operating profit decline, while outlining strategic investments in pipeline and digital transformation.
Key Events · Corporate Governance and Compliance · TAK
-
FY2025 Financial Performance
Reported a net loss of JPY 152.4 billion (USD 958 million) and negative EPS of JPY 97, primarily due to a $2.5 billion AMITIZA antitrust litigation provision. Core revenue declined 2.6% at constant exchange rates (CER).
-
FY2026 Financial Outlook
Forecasts a low-single digit core revenue decline and a 5-8% decline in core operating profit at CER, reflecting significant investments in new product launches and R&D.
-
Dividend Increase
Plans to increase the annual dividend per share to JPY 204.
-
Pipeline Advancement
Expects to launch three new products (oveporexton, rusfertide, zasocitinib) in the next 12 months and initiated Phase 3 studies for two other assets.
Analysis · TAK · Life Sciences
The Annual Integrated Report provides a comprehensive overview of Takeda's performance. The FY2025 reported net loss and negative EPS are significant, primarily driven by the previously disclosed AMITIZA antitrust litigation provision. The FY2026 financial outlook indicates a challenging near-term period with expected declines in core revenue and core operating profit, as the company prioritizes substantial investments in new product launches and R&D. While these investments are crucial for future growth, they will impact profitability in the short term. The planned dividend increase offers a positive signal for shareholder returns, and pipeline advancements provide long-term potential.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TAK was trading at $15.84 on NYSE in the Life Sciences sector, with a market capitalization of approximately $49.2B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.